Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

Home Case Index All Cases Central Excise Central Excise + AT Central Excise - 2018 (2) TMI AT This

  • Login
  • Cases Cited
  • Summary

Forgot password       New User/ Regiser

⇒ Register to get Live Demo



 

2018 (2) TMI 994 - AT - Central Excise


Issues involved:
1. Valuation of P&P medicines for duty payment.
2. Assessment of physician samples for free distribution.
3. Refund claims based on Supreme Court judgment.
4. Application of Central Excise Act for valuation.
5. Justification of refunds and unjust enrichment.
6. Imposition of interest amount and penalty.

Analysis:

Issue 1: Valuation of P&P medicines for duty payment
The appeals involved the issue of the valuation of P&P medicines for duty payment. The department contended that physician samples should be assessed under Rule 4 of the Central Excise Valuation Rules, 2000, based on the MRP of the goods. The appellants paid duty based on this view but later filed refund claims after a Supreme Court decision. The original authority and Commissioner (Appeals) upheld the duty payment, leading the matter to the Tribunal.

Issue 2: Assessment of physician samples for free distribution
The dispute also centered around the assessment of physician samples for free distribution without MRP/RSP affixed on the medicines. The department's view was based on a circular that the value should be determined under Rule 4 of the Valuation Rules. The appellants sought refunds based on subsequent judgments, including the Supreme Court decision in CCE, SURAT Vs. SUN PHARMACEUTICALS INDS. LTD., which held that valuation should be based on the contract price between the parties.

Issue 3: Refund claims based on Supreme Court judgment
The Ld. Consultant argued that the issue was settled by various judgments, including the one by the Supreme Court, making the refunds eligible. The Tribunal agreed, citing the SUN PHARMACEUTICALS INDS. LTD. case and subsequent decisions. The matter was remanded back to the original authority to examine the refund's impact on unjust enrichment, ensuring the appellants have the opportunity to present additional evidence.

Issue 4: Application of Central Excise Act for valuation
The Tribunal found the consultant's reliance on the SUN PHARMACEUTICALS INDS. LTD. case to be correct, as it aligned with the facts of the present appeal. The Tribunal noted that the case law's ratio had been followed in subsequent judgments, indicating that the refunds were sanctionable under Section 4(1)(a) of the Central Excise Act, 1944.

Issue 5: Justification of refunds and unjust enrichment
The Tribunal determined that the refunds were sanctionable based on the applicable case law. However, to address the issue of unjust enrichment, the matter was remanded to the original authority. The Tribunal emphasized providing the appellants with ample opportunity to present their case and any additional documents during the proceedings.

Issue 6: Imposition of interest amount and penalty
In a parallel appeal, the original authority confirmed an interest amount and imposed a penalty. However, as the primary issue in favor of the appellants was decided in the other appeals, this appeal was allowed by setting aside the upheld demand of interest and penalty.

In conclusion, all three appeals were disposed of based on the above analysis, with the matter remanded for further consideration on the issue of unjust enrichment.

 

 

 

 

Quick Updates:Latest Updates